Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

2 1

What is this study about?

This clinical trial is focused on studying Sjögren’s Syndrome, a condition that affects the body’s moisture-producing glands, leading to symptoms like dry mouth and eyes. The study will evaluate a treatment called HZN-1116, which is a solution for injection. The purpose of the study is to assess how effective and safe HZN-1116 is for people with this condition.

Participants in the study will receive either the HZN-1116 treatment or a placebo, which is a substance with no active medication. The study will be conducted over a period of time, during which participants will receive regular injections and attend follow-up visits to monitor their health and any changes in their symptoms. The study aims to understand how HZN-1116 affects the overall symptoms and quality of life for those with moderate to severe Sjögren’s Syndrome.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how the treatment impacts their condition. The study will help determine if HZN-1116 can be a beneficial treatment option for people living with Sjögren’s Syndrome.

1 joining the study

Upon joining the study, you will be randomly assigned to one of two groups. One group will receive the investigational medication HZN-1116, and the other group will receive a placebo, which is a substance with no active medication. This process is called a double-blind study, meaning neither you nor the study team will know which group you are in.

2 medication administration

If you are in the group receiving HZN-1116, the medication will be administered as a solution for injection under the skin, known as subcutaneous use. The frequency and dosage will be determined by the study protocol, and you will be informed of the schedule during your visits.

If you are in the placebo group, you will receive a commercially available saline solution administered in the same manner.

3 regular visits

You will be required to attend regular visits to the study site. During these visits, your health will be monitored, and various assessments will be conducted to evaluate the effects of the treatment. These assessments may include physical examinations, blood tests, and questionnaires about your symptoms and overall well-being.

4 monitoring and assessments

Throughout the study, your progress will be closely monitored. This includes tracking any changes in your symptoms of Sjögren’s Syndrome, such as dryness, pain, and fatigue. You will be asked to report any side effects or changes in your condition to the study team.

5 end of study

At the end of the study period, you will have a final visit where comprehensive assessments will be conducted. This will help determine the overall impact of the treatment on your condition. You will be informed about the next steps and any follow-up care that may be necessary.

Who Can Join the Study?

Adults aged between 18 and 75 years old can participate. Participants must be able to give their own consent to join the study.
Must have been diagnosed with Sjögren’s Syndrome according to specific medical criteria. If the diagnosis is based on a positive test for anti-Ro autoantibodies, this must be confirmed by a central laboratory.
For Population #1: Must have a score of 5 or more on the ESSDAI test, which measures disease activity, even after using treatments like nonsteroidal anti-inflammatory drugs (NSAIDs) or local therapies. Some areas of the body will be checked but won’t count towards the score needed to join.
For Population #2: Must have a score of 5 or more on the ESSPRI test, which measures symptoms reported by the patient, and a score of less than 5 on the ESSDAI test.
Must test positive for either anti-Ro autoantibodies or rheumatoid factor (RF), or both, at the screening.
Must have some remaining function in the salivary glands, shown by a saliva flow rate of more than 0.1 mL per minute, or some remaining function in the tear glands, shown by a Schirmer’s test result of 5 mm or more in 5 minutes.
Females who can have children and are sexually active with a male partner must use a highly effective method of birth control from the time they sign the consent form until the end of the study or 4 months after leaving the study. They must also agree not to donate eggs during this time.
Nonsterilized males who are sexually active with a female partner who can have children must use a condom with spermicide until the end of the study and must not donate sperm during this time and for at least 90 days after the last dose of the study medication.
Must provide written informed consent and any other required authorizations before any study-related procedures are performed.
Must be fully vaccinated against COVID-19 according to local guidelines at least 2 weeks before screening, unless they refuse vaccination. Vaccination is allowed during the study but not during the screening period or within 2 weeks after the first dose of the study medication.

Who Cannot Join the Study?

Patients with other autoimmune diseases that are not well controlled. Autoimmune diseases are conditions where the body’s immune system attacks its own tissues.
Patients who have had a recent infection that required treatment with antibiotics or antiviral medications.
Patients who have received any live vaccines within the last 4 weeks. Live vaccines contain a small amount of the actual virus or bacteria.
Patients who are currently pregnant or breastfeeding.
Patients with a history of severe allergic reactions to medications or vaccines.
Patients who have participated in another clinical trial within the last 4 weeks.
Patients with a history of drug or alcohol abuse within the past year.
Patients with any other medical condition that the study doctors believe would make it unsafe for them to participate.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name	City	Country
Medizinische Universitaet Innsbruck	Innsbruck	Austria
Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Rome	Italy
Medizinische Hochschule Hannover	Hanover	Germany
Krakowskie Centrum Medyczne Sp. z o.o.	Cracow	Poland
Ambulatories For Specialized Outpatient Medical Help Medical Center Kyuchuk Parizh OOD	Plovdiv	Bulgaria
Medical University Of Vienna	Vienna	Austria
CENTRUM MEDYCZNE REUMA PARK	Warsaw	Poland
CHU Grenoble Alpes	La Tronche	France
Centre Hospitalier Universitaire De Bordeaux	Bordeaux	France
Medical University Of Graz	Graz	Austria
Futuremeds Sp. z o.o.	Wroclaw	Poland
Oncopole Claudius Regaud	Toulouse	France
Unidade Local De Saúde De Santa Maria, E.P.E.	Lisbon	Portugal

Other Sites

Site Name	City	Country
Narodowy Instytut Geriatrii Reumatologii I Rehabilitacji Im Prof. Dr Hab. Med. Eleonory Reicher	Warsaw	Poland
Show more
Diagnostics And Consultation Center Convex Ltd.	Sofia	Bulgaria
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone	Palermo	Italy
Asst Centro Specialistico Ortopedico Traumatologico Gaetano Pini Cto	Milan	Italy
Promed P.Lach R.Glowacki Sp. j.	Cracow	Poland
Centrum Badawcze Panaceum Agnieszka Brzezicka Magdalena Lenkiewicz Sp. z o.o.	Malbork	Poland
Hospital Quironsalud Sagrado Corazon	Sevilla	Spain
MVZ Rheumatologie und Autoimmunmedizin Hamburg GmbH	Hamburg	Germany
Hospital Universitario Virgen De Las Nieves	Granada	Spain
Unidade Local De Saude Do Alto Minho E.P.E.	Ponte De Lima	Portugal
Our Ladys Hospital Manorhamilton	Sligo	Ireland
Asklepieion Voulas General Hospital	Voula	Greece
Ospedale Galeazzi S.p.A.	Milan	Italy
Centre Hospitalier Universitaire De Montpellier	Montpellier	France
Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet	Budapest	Hungary
Hospital General Universitario De Castellon	Castello De La Plana	Spain
Uniwersytecki Szpital Kliniczny W Poznaniu	Poznan	Poland
Medical Center Artmed Ltd.	Plovdiv	Bulgaria
Medical Center Excelsior OOD	Sofia	Bulgaria
Universita’ Campus Bio-medico Di Roma	Rome	Italy
University Of Debrecen	Debrecen	Hungary
Universita’ Di Pisa	Pisa	Italy
Synexus Polska Sp. z o.o.	Poznan	Poland
Pratia S.A.	Skorzewo	Poland
Centro Hospitalar Universitario De Santo Antonio E.P.E.	Porto	Portugal
Beaumont Hospital	Dublin	Ireland
Mufmfjybb Ipqnwdbktt Cbbvlzzw Sxtpslbd Srf z ovmm	Warsaw	Poland
Sktmzxd Sxrz Dl Hseotpkaad	Barcelona	Spain
Egtmlimvym Krdmsow Sxqqeux	Thessaloniki	Greece
Lnune Gjoraqd Hwsuykpb Oz Agnjcs	Athens	Greece
Pitrmegv Pzpptyck Lngasqmo Pivg Ds Hpz Mmb Pvdka Hwrazu	Poznan	Poland
Mfjwbxst Mxjplhc Acaimvq	Pleven	Bulgaria
Hxlrwtsf Ufkimuqcomzzcu Silreyhrtt &mzlpfl Hvejkdr dm Hqfqmflebqg	STRASBOURG, Alsace	France

Trial status

Country	Status	Recruitment Start
Austria	Not recruiting	01.01.2025
Bulgaria	Not recruiting	01.01.2025
France	Not recruiting	01.01.2025
Germany	Not recruiting	01.01.2025
Greece	Not recruiting	01.01.2025
Hungary	Not recruiting	01.01.2025
Ireland	Not recruiting	01.01.2025
Italy	Not recruiting	01.01.2025
Poland	Not recruiting	01.01.2025
Portugal	Not recruiting	01.01.2025
Spain	Not recruiting	01.01.2025

Trial locations

Investigated drugs:

Vib1116

HZN-1116 is a medication being studied for its potential to help people with Sjögren’s Syndrome, a condition where the body’s immune system attacks its own moisture-producing glands. This can lead to symptoms like dry mouth and dry eyes, as well as other systemic issues. In this clinical trial, researchers are looking at how well HZN-1116 can reduce the overall disease activity in people who have moderate to severe symptoms. They are also interested in seeing if it can improve the symptoms that patients report, especially for those who feel their symptoms are not well managed. The goal is to find out if HZN-1116 can make a meaningful difference in the lives of people living with this condition.

Sjögren’s Syndrome – Sjögren’s Syndrome is an autoimmune disorder characterized by the body’s immune system mistakenly attacking its own moisture-producing glands. This leads to symptoms such as dry mouth and dry eyes. Over time, the disease can also affect other parts of the body, including the joints, skin, and organs like the kidneys and lungs. The progression of the disease can vary, with some individuals experiencing mild symptoms while others may develop more severe systemic manifestations. As the disease progresses, patients may experience fatigue, joint pain, and swelling. The condition can also lead to complications such as dental decay and oral infections due to reduced saliva production.

Trial ID:

2023-507680-19-00

Protocol code:

HZNP-HZN-1116-201

NCT ID:

NCT06312020

Trial Phase:

Therapeutic exploratory (Phase II)

Other Trials to Consider

#1 Clinical Trials Search in Europe

Study on the Effects of HZN-1116 for Patients with Sjögren’s Syndrome

What is this study about?

Who Can Join the Study?

Who Cannot Join the Study?